Senhwa Biosciences announced a clinical collaboration with BeOne Medicines to evaluate CX‑5461 combined with an antibody‑drug conjugate (ADC) and a marketed PD‑1 inhibitor in cold tumors, positioning the company to target a multi‑billion dollar market. The company framed CX‑5461 plus ADC as a potential 'blockbuster' combination and emphasized global commercialization ambitions. The release outlines clinical plans and market rationale, and signals growing industry interest in strategic combinations to convert immunologically cold tumors to responsive states. For readers: 'cold tumors' lack sufficient immune infiltration to respond to checkpoint inhibitors and are a key focus for combination strategies.